Cai et al. indicated that the level of SRC-3 was correlated with Gefitinib resistance in lung cancer and SRC-3 knockdown caused TKI-resistant lung cancer to be more sensitive to Gefitinib [60], which suggests SRC-3 may be a therapeutic target for lung cancer in combination with Gefitinib. This evidence concerns the gene NCOA3 and lung carcinoma.